Advances in Simultaneous RP-HPLC Methods for Multi-Component Analysis of Antidiabetic Drugs: A Comprehensive Review

Common Fixed-Dose Combinations (FDCs) in Diabetes Treatment

Fixed-dose combinations (FDCs) are widely prescribed to improve patient compliance, optimize therapeutic outcomes, and minimize pill burden (17). Some of the most common FDCs include Metformin + Sulfonylurea (e.g., Metformin + Glibenclamide), Metformin + DPP-4 inhibitor (e.g., Metformin + Sitagliptin), and Metformin + SGLT2 inhibitor (e.g., Metformin + Dapagliflozin). Triple-drug FDCs, such as Metformin + Pioglitazone + Glimepiride, are also increasingly used in cases where dual therapy fails to achieve glycemic control (11). These formulations not only enhance therapeutic synergy but also present unique analytical complexities due to the co-presence of chemically diverse drugs.

Analytical Challenges in Simultaneous Estimation

The simultaneous quantification of multiple antidiabetic drugs poses several analytical challenges. Differences in physicochemical properties such as polarity, solubility, and pKa often complicate chromatographic separation (7). Additionally, the wide concentration range between high-dose drugs like metformin and low-dose agents like glimepiride creates sensitivity-related issues in detection (3). Co-elution, overlapping UV absorbance spectra, and degradation products further limit accurate quantification (8). Thus, developing robust, validated, and eco-friendly analytical methods especially RP-HPLC is essential for routine quality control and regulatory compliance.

RP-HPLC Principles and Relevance in Antidiabetic Drug Analysis

Basic Principle of RP-HPLC

Reverse Phase High-Performance Liquid Chromatography (RP-HPLC) is a widely used chromatographic technique that separates analytes based on their hydrophobic interactions with a non-polar stationary phase and a polar mobile phase (18). Typically, C18 or C8 silica-based columns are employed, where non-polar compounds exhibit longer retention times compared to polar compounds (19). The flexibility of RP-HPLC allows modification of the mobile phase composition, pH, and flow rate to achieve optimal separation, making it particularly suitable for multi-component drug formulations (8).

Advantages in Simultaneous Multi-Drug Analysis

RP-HPLC has several advantages in analyzing multi-component pharmaceutical formulations. It offers high sensitivity, enabling the detection of drugs even at very low concentrations. The technique is highly reproducible, ensuring consistency across multiple runs and laboratories (9). Moreover, its robustness allows it to tolerate small variations in parameters such as temperature, pH, and flow rate without significant loss of resolution (20). These qualities make RP-HPLC the method of choice for routine analysis of fixed-dose combinations of antidiabetic drugs.

Comparison with Other Analytical Techniques

Although other analytical methods such as UV-spectrophotometry, spectrofluorimetry, and LC-MS/MS are used in pharmaceutical analysis, each has limitations compared to RP-HPLC. UV-spectrophotometry is simple and cost-effective but lacks specificity in multi-component analysis due to overlapping absorption spectra (12). Spectrofluorimetry provides higher sensitivity than UV methods but is limited to fluorescent compounds and often requires derivatization steps. LC-MS/MS, while highly sensitive and selective, involves higher costs, complex instrumentation, and extensive sample preparation, limiting its routine use in quality control (21). In contrast, RP-HPLC provides the best balance of sensitivity, selectivity, reproducibility, and cost-effectiveness, making it the gold standard for simultaneous estimation of antidiabetic drugs.

METHOD DEVELOPMENT STRATEGIES:

Selection of Stationary and Mobile Phases

The selection of appropriate stationary and mobile phases is critical for successful separation in RP-HPLC. Non-polar stationary phases such as octadecylsilane (C18) are most commonly used due to their ability to provide excellent resolution for a wide variety of drug molecules (18). The mobile phase typically consists of a mixture of water (or buffer) and organic solvents such as methanol or acetonitrile, which are chosen based on analyte solubility and retention behavior (22). Proper selection helps in achieving shorter run times and better peak symmetry (20).

pH and Buffer Optimization

pH plays a vital role in controlling the ionization state of analytes, which directly affects their retention time and resolution. For weakly acidic or basic drugs, selecting an optimal pH (usually between 2.5–7.5) ensures consistent ionization and sharp peaks (23). Buffers such as phosphate or acetate are often used to maintain pH stability during analysis. Incorrect pH can lead to peak tailing, poor reproducibility, and reduced column life.

Column Selection (C18, C8, etc.)

Column selection is crucial for resolving drugs with diverse physicochemical properties. C18 columns are the most widely used due to their high hydrophobic interactions and versatility (18). However, shorter-chain columns such as C8 or phenyl columns may be preferable for highly hydrophobic drugs or when faster analysis is required (8). Selection often depends on the complexity of the drug mixture and desired run time (24).

Gradient vs Isocratic Methods

Both gradient and isocratic elution methods are employed in RP-HPLC. Isocratic methods are simple, reproducible, and suitable for formulations with analytes of similar polarity. However, gradient methods, which involve a gradual change in the composition of the mobile phase, are advantageous for complex mixtures of drugs with wide polarity differences, as they improve resolution and reduce analysis time (19). Gradient elution is particularly useful for simultaneous estimation of multi-component antidiabetic formulations (17).

Internal Standards and Detection Wavelengths

The use of internal standards is common in RP-HPLC to compensate for variability in sample preparation and injection volume. Internal standards must be chemically stable, non-interfering, and elute close to the analyte of interest (17). Detection is typically carried out using UV detectors at specific wavelengths corresponding to the absorption maxima of the analytes. For example, metformin is often detected around 233 nm, while sulfonylureas may be detected near 230–250 nm (3). The selection of an optimal wavelength ensures maximum sensitivity and specificity, minimizing baseline noise and co-elution interferences (9).

VALIDATION PARAMETERS

Analytical method validation is essential to ensure the reliability, reproducibility, and regulatory acceptance of RP-HPLC methods. The International Council for Harmonisation (ICH) Q2(R1) guidelines provide a framework for validating analytical methods in terms of accuracy, precision, linearity, specificity, sensitivity, robustness, and quantitation limits (ICH 2005). (25)

Accuracy

Accuracy refers to the closeness of the measured values to the true value or standard reference. It is typically assessed by recovery studies, where a known amount of drug is added to the formulation, and the percentage recovery is calculated.

Precision

Precision indicates the degree of repeatability under normal operating conditions. It is expressed as intra-day and inter-day variability, measured through relative standard deviation (%RSD) (9). Low %RSD values confirm high precision of the developed method.

Linearity

Linearity demonstrates the ability of the method to produce results directly proportional to the concentration of the analyte across a specific range (19). Calibration curves are typically plotted with correlation coefficients (r²) greater than 0.999, ensuring reliable quantification of antidiabetic drugs (7).

Specificity

Specificity is the method’s ability to unequivocally assess the analyte in the presence of components such as impurities, excipients, or degradation products (20). RP-HPLC methods are highly specific when optimized with suitable stationary phases and mobile phases, minimizing co-elution.

Sensitivity

Sensitivity is determined by the method’s ability to detect and quantify low concentrations of analytes. In RP-HPLC, sensitivity depends on detector selection (commonly UV or PDA detectors) and optimized chromatographic conditions.

Robustness

Robustness evaluates the capacity of a method to remain unaffected by small but deliberate variations in parameters such as pH, mobile phase composition, or flow rate (12). Robust methods are essential for routine quality control testing of multi-component formulations.

LOD (Limit of Detection) and LOQ (Limit of Quantification)

LOD is the lowest amount of analyte that can be detected but not necessarily quantified, while LOQ is the lowest amount that can be quantitatively determined with acceptable precision and accuracy (ICH 2005). These values are calculated based on the standard deviation of the response and the slope of the calibration curve (3).

Application in Stability and Bioequivalence Studies

Validated RP-HPLC methods are frequently applied in stability testing to monitor degradation products under stress conditions such as heat, light, and oxidation (7). They are also used in bioequivalence studies, where drug concentrations in biological samples such as plasma or serum are analyzed to establish therapeutic equivalence of generic formulations (21). These applications highlight the importance of validated methods in ensuring patient safety and regulatory compliance.

Advances in Simultaneous RP-HPLC Methods

Recent Trends in Antidiabetic Multi-Component Analysis

The growing complexity of fixed-dose combinations (FDCs) in diabetes management has accelerated research into efficient RP-HPLC methods for simultaneous estimation. Recent developments have focused on shortening analysis times, improving resolution, and enhancing sensitivity through optimized mobile phase compositions and advanced detectors. Method miniaturization and automation are emerging trends, enabling high-throughput analyses in both pharmaceutical quality control and clinical settings (8).

Case Studies of Dual/Triple Drug Combinations

Several successful RP-HPLC methods have been developed for the simultaneous quantification of dual and triple antidiabetic drug combinations. For instance, validated methods for Metformin + Sitagliptin have demonstrated high accuracy and reproducibility, supporting their application in routine quality control (22). Similarly, simultaneous estimation of Glibenclamide + Metformin + Pioglitazone has been achieved using gradient elution with excellent linearity and sensitivity (7). These case studies illustrate RP-HPLC’s versatility in handling chemically diverse analytes within a single analytical run.

Use of Green Chemistry Approaches

In alignment with sustainable pharmaceutical analysis, recent studies have explored green RP-HPLC methods that use eco-friendly solvents such as ethanol or water-based buffers instead of conventional acetonitrile and methanol (23). These methods not only reduce environmental hazards but also minimize costs while maintaining high analytical performance (24). Additionally, reduced run times and solvent consumption support eco-efficiency, making green chromatography a promising area for future research in antidiabetic drug analysis.

Automated RP-HPLC and Hyphenated Techniques (RP-HPLC-MS)

The integration of RP-HPLC with automation and hyphenated techniques has significantly advanced analytical capabilities. Automated RP-HPLC systems now allow real-time monitoring, auto-sampling, and enhanced reproducibility in routine assays (19). Furthermore, coupling RP-HPLC with Mass Spectrometry (RP-HPLC-MS) enhances specificity and sensitivity, enabling detection of trace levels of antidiabetic drugs and their metabolites in biological fluids (27). This hyphenated approach is increasingly applied in pharmacokinetic studies, bioequivalence testing, and drug discovery.

Applications in Pharmaceutical And Clinical Research

Quality Control of Marketed Formulations

RP-HPLC is extensively used in quality control laboratories to ensure the purity, potency, and consistency of marketed antidiabetic formulations. Its ability to simultaneously estimate multiple active ingredients makes it indispensable in routine batch release testing (3). By meeting pharmacopeial standards and ICH validation criteria, RP-HPLC contributes to regulatory compliance and ensures patient safety (8).

Bioanalytical Applications in Plasma/Serum Drug Estimation

In clinical research, RP-HPLC plays a central role in bioanalytical assays for estimating antidiabetic drug concentrations in biological fluids such as plasma and serum (28). These applications are crucial for monitoring therapeutic drug levels, assessing bioavailability, and ensuring patient compliance (29). When coupled with advanced detectors or mass spectrometry, RP-HPLC enables the detection of trace drug levels and metabolites in complex biological matrices (30).

Pharmacokinetic and Pharmacodynamic Studies

Pharmacokinetic (PK) and pharmacodynamic (PD) studies require highly sensitive and reproducible methods for quantifying drugs in biological systems. RP-HPLC has been successfully applied in determining critical PK parameters such as maximum plasma concentration (Cmax), time to reach Cmax (Tmax), and elimination half-life (t1/2) of antidiabetic drugs (31). Such studies provide essential data for dose optimization and safety evaluation during drug development and clinical trials (32).

Regulatory Acceptance in Generic Formulations

The pharmaceutical industry increasingly relies on RP-HPLC for demonstrating bioequivalence between branded and generic formulations. Regulatory agencies such as the USFDA and EMA mandate validated RP-HPLC methods for establishing equivalence in dissolution and bioavailability studies (ICH 2005). Successful validation ensures the generic product’s therapeutic equivalence to innovator drugs, thereby facilitating market approval and patient accessibility (33).

LIMITATIONS AND CHALLENGES

Co-Elution and Interference in Multi-Drug Analysis

One of the major challenges in simultaneous RP-HPLC analysis of antidiabetic drugs is co-elution, where analytes or their impurities overlap due to similar physicochemical properties (34). This can result in poor resolution and inaccurate quantification, particularly in fixed-dose combinations where drugs differ widely in concentration levels. Advanced optimization of chromatographic parameters or gradient elution methods is often required to overcome such issues (35).

Stability Issues in RP-HPLC Methods

Stability of analytes under varying chromatographic and storage conditions poses another limitation. Many antidiabetic drugs, such as sulfonylureas and gliptins, are prone to degradation when exposed to light, heat, or oxidative conditions (36). Instability can lead to secondary peaks, poor reproducibility, and unreliable results (37). Stress testing and stability-indicating RP-HPLC methods are therefore necessary to ensure accuracy during routine analysis (38).

High Cost and Technical Expertise Requirements

Although RP-HPLC is the gold standard, its application is constrained by high operational costs (instrumentation, solvents, and maintenance) and the need for trained personnel to optimize methods (39). Compared to simpler techniques like UV spectrophotometry, RP-HPLC requires specialized knowledge of column chemistry, buffer preparation, and detector calibration, limiting its accessibility in resource-constrained settings (40).

Need for Improved Eco-Friendly Solvents and Rapid Methods

The use of conventional solvents like acetonitrile and methanol in RP-HPLC raises concerns regarding cost, toxicity, and environmental sustainability (41). There is a growing demand for green RP-HPLC methods, using eco-friendly solvents such as ethanol or water-based systems, which minimize environmental hazards while maintaining analytical efficiency (42). Furthermore, traditional RP-HPLC methods often involve longer run times, which hinder high-throughput analysis. The development of rapid, miniaturized, and automated RP-HPLC techniques is essential for addressing future pharmaceutical and clinical demands.

FUTURE DIRECTIONS

Integration with LC-MS/MS for Improved Sensitivity

Future advancements in analytical chemistry are expected to focus on hyphenated techniques such as RP-HPLC coupled with mass spectrometry (LC-MS/MS), which offer higher selectivity and sensitivity for trace-level detection of antidiabetic drugs and their metabolites (43). Such integration enables simultaneous qualitative and quantitative analysis, making it highly useful for pharmacokinetic studies and bioequivalence testing (44, 45).

Development of Universal RP-HPLC Methods for Multiple Classes of Antidiabetics

A significant research direction lies in designing universal RP-HPLC methods capable of simultaneously analyzing multiple classes of antidiabetic drugs with diverse physicochemical properties (46). By standardizing column chemistry, buffer systems, and detection parameters, such universal methods could reduce the need for multiple drug-specific validations and streamline pharmaceutical analysis (47).

Miniaturized and High-Throughput Methods

With the growing demand for rapid quality control and clinical monitoring, miniaturized and high-throughput RP-HPLC systems are gaining attention. Techniques such as ultra-high-performance liquid chromatography (UHPLC) offer shorter run times, smaller solvent consumption, and improved resolution (48, 49). These advancements can significantly enhance analytical productivity while reducing operational costs in large-scale pharmaceutical industries (50).

Green Analytical Chemistry Applications in RP-HPLC

Sustainability is increasingly influencing pharmaceutical research, and the development of green RP-HPLC methods is a priority. Strategies include replacing hazardous solvents with ethanol or water-based systems, reducing analysis time, and minimizing waste generation (51). The application of green chemistry principles will not only reduce environmental impact but also align analytical practices with regulatory trends encouraging eco-friendly technologies (52).

CONCLUSION

Reverse-phase HPLC continues to be the workhorse and gold-standard for simultaneous estimation of multi-component antidiabetic formulations due to its balance of selectivity, sensitivity, reproducibility, and regulatory acceptability. Ongoing advances in method development—including smarter mobile-phase design, judicious column selection, and optimized gradients—have reduced run times, improved resolution at disparate dose levels, and enhanced ruggedness, thereby improving speed, accuracy, and cost-effectiveness in routine QC and bioanalytical settings. Looking ahead, research should prioritize eco-friendly and high-throughput strategies—such as green solvent systems, UHPLC miniaturization, and automation—and greater hyphenation with MS to extend sensitivity and selectivity for complex matrices. Collectively, these directions will consolidate RP-HPLC’s central role while aligning analytical practice with sustainability and next-generation clinical and regulatory demands.

REFERENCES

1. American Diabetes Association (2023). Standards of Medical Care in Diabetes—2023. Diabetes Care, 46(Suppl 1): S1–S291.
2. International Diabetes Federation (2021). IDF Diabetes Atlas, 10th ed. Brussels: IDF.
3. Patel B. A., Patel F. N., Pande A. K., Patel U. R, (2024), Analytical method of development and validation for determination of Canaglifozin and Metformin in API and synthetic mixture by RP HPLC, Discover Chemistry, 1:63.
4. ICMR Guidelines for Management of Type 2 Diabetes 2018.
5. Tiwari S S, Wadher S J, Fartade S J and Vikhar C N, Gliflozin A New Class For Type-II Diabetes Mellitus: An Overview, International Journal of Pharmaceutical Sciences and Research, 2019; Vol. 10(9): 4070-4077.
6. Reckless J P D, What is diabetes? The classification of different types of diabetes mellitus, Practical Diabetes, jan/Feb 1985, Vol 2, No 1.
7. Babu, K. S., & Rao, R. N. (2011). RP-HPLC of Glibenclamide, Metformin, and Pioglitazone. J. Pharm. Biomed. Anal., 56: 221–228.
8. Sahu, P. K., Ramisetti, N. R., Cecchi, T., Swain, S., & Patro, C. S. (2018). HPLC Method Development and Validation—A Review. J. Pharm. Biomed. Anal., 147: 590–611.
9. Gupta R, Saxena A M, Ahmad A, Singh A K, Chaurasiya R and Gupta M, Antidiabetic compounds from Swertia chirayita for the treatment of type 2 diabetes mellitus: A mechanistic overview, International Journal of Phytomedicines and Related Industries, Medicinal Plants, Vol. 16 (4), (2024), 625-634.
10. Tiwari R, Singh S, Bajpei M, Verma N, Verma S, Impact of Osteocalcin on Glycemic Regulation and Insulin Sensitivity in Type 2 Diabetes Mellitus Patients, Cureus 16(10), (2024)
11. Foretz M, Guigas B, Viollet B, Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus, Nat Rev Endocrinol, 2019 Oct;15(10):569-589.
12. Kalra S, Jena B N, Yeravdekar R, Emotional and Psychological Needs of People with Diabetes, Indian J Endocrinol Metab, 2018 Sep-Oct;22(5):696-704.
13. Raymond E. Soccio, Eric R. Chen, Satyajit R. Rajapurkar, Pegah Safabakhsh, Jill M. Marinis, Joanna R. Dispirito, Matthew J. Emmett, Erika R. Briggs, Bin Fang, Logan J. Everett, Hee-Woong Lim, Kyoung-Jae Won, David J. Steger, Ying Wu, Mete Civelek, Benjamin F. Voight, and Mitchell A. Lazar, Genetic Variation Determines PPARg Function and Anti-diabetic Drug Response In Vivo, Cell 162, 33–44 July 2, 2015, Elsevier Inc.
14. Scheen A. J., Antidiabetic agents in subjects with mild dysglycaemia: prevention or early treatment of type 2 diabetes? Diabetes & Metabolism, Volume 33, Issue 1, February 2007, Pages 3-12.
15. Zinman B, Skyler J S., Riddle M C, Ferrannini E, Diabetes Research and Care Through the Ages, Diabetes Care 2017;40(10):1302–1313.
16. Nauck M A, Wefers J, Meier J J, Treatment of type 2 diabetes: challenges, hopes, and anticipated successes, The Lancet Diabetes & Endocrionology, Volume 9, Issue 8, P525-544 August 2021.
17. Singh O, Verma M, Dahiya N, Senapati S, Kakkar R, Kalra, Integrating Polygenic Risk Scores (PRS) for Personalized Diabetes Care: Advancing Clinical Practice with Tailored Pharmacological Approaches, Diabetes Ther (2025) 16:149–168.
18. Dong, M. W. (2013). Modern HPLC for Practicing Scientists. 2nd ed. Hoboken: Wiley.
19. Snyder, L. R., Kirkland, J. J., & Dolan, J. W. (2010). Introduction to Modern Liquid Chromatography. 3rd ed. Hoboken: Wiley.
20. Rao, R. N., & Babu, K. S. (2019). Strategies for Separation of Multi-Component Drug Products by RP-HPLC. J. Pharm. Biomed. Anal., 164: 129–146.
21. Niessen, W. M. A. (2017). Liquid Chromatography–Mass Spectrometry. 4th ed. Boca Raton: CRC Press.
22. Snyder, L. R., Dolan, J. W., & Gant, J. R. (1979). Gradient Elution in LC. J. Chromatogr., 165: 3–30.
23. Swartz, M. E., & Krull, I. S. (2012). Handbook of Analytical Validation. Boca Raton: CRC Press. USP (2024). General Chapter <621> Chromatography. United States Pharmacopeia–NF. Rockville, MD: USP.
24. Chandran E. A., Vineesha M., N. Mathew Valooran, A. Kumar R., A Recent Update on Pyridine Derivatives as a Potential Lead for Diabetes Mellitus. J. Chem. Rev., 2023, 5(2), 159-182.
25. ICH (2005). Q2(R1): Validation of Analytical Procedures: Text and Methodology. Geneva: ICH.
26. Dong, M. W. (2006). Modern LC Detectors. LCGC North America, 24(5): 498–510.
27. Ga?uszka, A., Migaszewski, Z., Konieczka, P., & Namie?nik, J. (2013). Green Analytical Chemistry: Theory and Practice. Chem. Soc. Rev., 42(16): 6344–6363.
28. P?otka-Wasylka, J. (2018). A New Tool for the Evaluation of the Greenness of Analytical Procedures: Green Analytical Procedure Index. Talanta, 181: 204–209.
29. P?otka-Wasylka, J., & Ko?odziejczak-Radzimska, A. (2021). Metrics in Green Analytical Chemistry. TrAC Trends Anal. Chem., 137: 116206.
30. Pena-Pereira, F., Wojnowski, W., & Tobiszewski, M. (2020). AGREE—Analytical GREEnness Metric. Anal. Chem., 92(14): 10076–10082.
31. Niessen, W. M. A. (2006). Advances in LC-MS Interfaces. J. Chromatogr. A, 1109: 1–31.
32. Blessy, M., Patel, R. D., Prajapati, P. N., & Agrawal, Y. K. (2014). Development of Forced Degradation and Stability Indicating Methods—A Review. J. Pharm. Anal., 4(3): 159–165.
33. Kazakevich, Y., & Lobrutto, R. (2007). HPLC for Pharmaceutical Scientists. Hoboken: Wiley.
34. Snyder, L. R., Dolan, J. W., & Carr, P. W. (2014). The Hydrophobic-Subtraction Model of Reversed-Phase Column Selectivity. J. Chromatogr. A, 1060: 77–116.